I have a very simplistic view of Brilacidin since
Post# of 72446
(Total Views: 552)
Posted On: 03/07/2020 10:48:56 AM
I have a very simplistic view of Brilacidin since I have absolutely no medical background but after having read a great deal from the company website and reading posts for many years (I was originally in CTIX before the start of any clinical trials, before we bought Polymedix (Brilacidin), while Dr. Menon was still the main focus of IPIX, and having drugs brought to market just a many years dream down the line) I have reached the following conclusions in regards to what B can do and if it appears B can do such things safely. I am not a great one to catalog everything I hear or read so I cannot give references to my statements other than that I didn't just pull them out of thin air:
The greatest statement about the properties of Brilacidin I believe came from the originators of this "de novo" small molecule - Brilacidin as a defensin mimetic (mimetic as it is a synthetic molecule mimicking a natural defensin) is 100 times as powerful and 1,000 times as selective as a natural defensin. The power of the drug is what will/has made it efficacious in trials and will make it so valuable in the real world (especially in respiratory cases where both its anti-bacterial and anti-inflammatory properties will play the major roles), possibly in some sort of anti-virol capacity (if this occurs a great 'icing on the cake'), and its selectivity (1000 times that of a natural) is what will make it such a safe drug. I am not completely sure as to just what this 'selectivity' means (I know if we were talking Kevetrin it means it does not bother good cells/DNA, just cancerous cells) but IMO it should indicate that maybe it won't go helter skelter crazy against good bacteria like it does against bad bacteria (but then again, how would it be able to determine that?). Would appreciate info if anybody has it in regards to what this selectivity enhancement actually means.
Brilacidin does not cause systemic buildup in trials to date which makes me believe it clears the body fast, it seems to not interfere with other medications, and does not cause any types of major side issues with patients in regards to causing pain or becoming uncomfortable.
Corona... studies by labs and universities IMO regarding B is so major IMO because it will highlight the power of B to aid in many, if not all, respiratory conditions. The COPD/Asthma market by 2022 will be about $50B/yr, the influenza revenues currently dwarf the corona revenues as the cases are in the millions per year and deaths in the tens of thousands so many, many opportunities for it to be used in the most severe cases (those serious enough to cause death) year in and year out for the flu, and there are many other respiratory conditions B should aid. I am thinking of a possible inhaler for these types of conditions.
As evident from above, the TOTAL revenues of Brilacidin should exceed those of Kevetrin for cancer as cancer is about $100B/yr (at least that is what I have come to think of the market) and B for IBD and respiratory alone is going to be around $100B and we have not even scratched the surface of other possible uses for B.
In my opinion, the monies and studies afforded B by govt studies for corona will bring B to the forefront of medical attention immediately and allow for B indications to reach the public oh so much quicker than if IPIX had to fund all the research by themselves.
My views above I can guarantee probably have some errors, I am again not an expert and don't try to pass myself off as one, what I write is to mainly garner readers to question everything about IPIX/B and come to your own conclusions as to the value of the Brilacidin platform and ultimately IPIX.
I am getting a kick out of the newbies who are almost wetting themselves because of a 43% price rise from .115 to .16 Friday when in the long run it doesn't mean squat. We will soon hit dollars, multi-dollars, and somewhere down the line double digit dollars with triple digit numbers not out of the question. It won't be overnight, though it could get some major spikes at any time, and in the most important aspect the future of IPIX has become so much more solidified just since the beginning of 2020.
The greatest statement about the properties of Brilacidin I believe came from the originators of this "de novo" small molecule - Brilacidin as a defensin mimetic (mimetic as it is a synthetic molecule mimicking a natural defensin) is 100 times as powerful and 1,000 times as selective as a natural defensin. The power of the drug is what will/has made it efficacious in trials and will make it so valuable in the real world (especially in respiratory cases where both its anti-bacterial and anti-inflammatory properties will play the major roles), possibly in some sort of anti-virol capacity (if this occurs a great 'icing on the cake'), and its selectivity (1000 times that of a natural) is what will make it such a safe drug. I am not completely sure as to just what this 'selectivity' means (I know if we were talking Kevetrin it means it does not bother good cells/DNA, just cancerous cells) but IMO it should indicate that maybe it won't go helter skelter crazy against good bacteria like it does against bad bacteria (but then again, how would it be able to determine that?). Would appreciate info if anybody has it in regards to what this selectivity enhancement actually means.
Brilacidin does not cause systemic buildup in trials to date which makes me believe it clears the body fast, it seems to not interfere with other medications, and does not cause any types of major side issues with patients in regards to causing pain or becoming uncomfortable.
Corona... studies by labs and universities IMO regarding B is so major IMO because it will highlight the power of B to aid in many, if not all, respiratory conditions. The COPD/Asthma market by 2022 will be about $50B/yr, the influenza revenues currently dwarf the corona revenues as the cases are in the millions per year and deaths in the tens of thousands so many, many opportunities for it to be used in the most severe cases (those serious enough to cause death) year in and year out for the flu, and there are many other respiratory conditions B should aid. I am thinking of a possible inhaler for these types of conditions.
As evident from above, the TOTAL revenues of Brilacidin should exceed those of Kevetrin for cancer as cancer is about $100B/yr (at least that is what I have come to think of the market) and B for IBD and respiratory alone is going to be around $100B and we have not even scratched the surface of other possible uses for B.
In my opinion, the monies and studies afforded B by govt studies for corona will bring B to the forefront of medical attention immediately and allow for B indications to reach the public oh so much quicker than if IPIX had to fund all the research by themselves.
My views above I can guarantee probably have some errors, I am again not an expert and don't try to pass myself off as one, what I write is to mainly garner readers to question everything about IPIX/B and come to your own conclusions as to the value of the Brilacidin platform and ultimately IPIX.
I am getting a kick out of the newbies who are almost wetting themselves because of a 43% price rise from .115 to .16 Friday when in the long run it doesn't mean squat. We will soon hit dollars, multi-dollars, and somewhere down the line double digit dollars with triple digit numbers not out of the question. It won't be overnight, though it could get some major spikes at any time, and in the most important aspect the future of IPIX has become so much more solidified just since the beginning of 2020.
(15)
(0)